share_log

BTIG Upgrades Outlook Therapeutics to Buy, Announces $50 Price Target

Moomoo 24/7 ·  Mar 27 07:19

BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $50 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment